IJR News - today's news from every side

IJR News - today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Congress

Genius — OpenServe

Tiziana Reports Foralumab Meets MS Trial EndpointsHealth — Nov 2, 2026Tiziana Life Sciences said its Phase 2a trial of intranasal foralumab in non-active secondary progressive MS met its primary endpoints, with the 50-microgram dose significantly reducing a measure of brain inflammation and both doses showing a favorable safety profile. Patients also reported improved fatigue, but disability scores did not change during the 12-week study; the company plans further analysis and discussions on next steps.

0

Tiziana Executive Chairman Raises Stake to 34.93% — Jul 22, 2026Tiziana Life Sciences’ Executive Chairman Gabriele Cerrone has quietly increased his stake to 34.93% via Panetta Partners, purchasing 42,357 shares at $0.99, signaling strong insider confidence in the clinical-stage biotech’s lead asset intranasal foralumab. The move could bolster governance, financing, and partnership prospects as the company advances its MS-focused immunomodulation programs.

0